Highlight Articles in Int J Ophthalmol Vol.14 No.11 2021
  • Share:

Highlight Articles in Int J Ophthalmol Vol.14 No.11 2021

  

REVIEW AND COMMENTARY

Effect of anti-VEGF treatment on nonperfusion areas in ischemic retinopathy

Zi-Yi Zhu, Yong-An Meng, Bin Yan, Jing Luo

 

In recent years, retinal ischemia such as that which occurs in diabetic retinopathy (DR) and retinal vein occlusion (RVO) has become a hotspot of ischemic retinopathy research. High levels of vascular endothelial growth factor (VEGF) are recognized as a major cause of macular edema (ME) in DR and RVO. High concentrations of VEGF in the vitreous can lead to serious retinal ischemia and hypoxia and form retinal nonperfusion areas (NPAs). Different levels of retinal ischemia can represent disease severity and progression. Anti-VEGF therapy as the first-line treatment for ME has been found to be effective in improving vision, but there are still disputes about whether anti-VEGF therapy could improve retinal ischemia and achieve reperfusion of previously developed retinal NPAs. The authors review and summarize studies of the effects of anti-VEGF drugs on retinal ischemia, especially NPAs.

 

对照译文

抗血管内皮生长因子治疗缺血性视网膜病变对无灌注区的影响

 

近年来,糖尿病视网膜病变(DR)和视网膜静脉阻塞(RVO)等引起的视网膜缺血已成为缺血性视网膜病变研究的热点。高水平的血管内皮生长因子(VEGF)被认为是DRRVO黄斑水肿(ME)的主要原因。玻璃体中高浓度的VEGF可导致严重的视网膜缺血和缺氧,并形成视网膜无灌注区。不同程度的视网膜缺血可代表疾病的严重程度和进展。抗VEGF治疗作为ME的首选治疗方法能有效改善视力,但抗VEGF治疗是否能改善视网膜缺血并实现视网膜无灌注区的再灌注仍存在争议。该文回顾和总结了抗VEGF药物对视网膜缺血,特别是对视网膜无灌注区的影响。

PDF Fulltext

 

BASIC RESEARCH

Inhibition of corneal neovascularization by topical application of nintedanib in rabbit models

Juan Chen, Xue Ding, Wei Du, Xin Tang, Wen-Zhen Yu

 

Corneal neovascularization (NV) refers to a pathological change, that can cause opacification of cornea and subsequently diminishing vision. Several treatment options are currently in use to treat corneal NV, including steroids and nonsteroidal anti-inflammatory agents, photodynamic therapy and photocoagulation, but efficacies are limited, and side effects have been reported. This study was designed to evaluate the potential efficacy and mechanisms of nintedanib in corneal NV in rabbit models. Corneal NV was induced using 1 mol/L NaOH, 21 rabbits were randomized to 3 groups, treated with 0.9% NaCl, Avastin (5 mg/mL), nintedanib (1 mg/mL), respectively. The result shows that nintedanib and Avastin can effectively inhibit corneal NV, with P38 MAPK and AKT signaling pathways being possibly involved. Nintedanib seems more effective than Avastin and has the potential to be a novel therapy for preventing corneal NV.

 

对照译文

局部使用尼达尼布对兔角膜新生血管的抑制作用

 

角膜新生血管(NV)是一种病理变化,可导致角膜混浊和视力下降。目前有几种治疗方法用于治疗角膜NV,包括类固醇和非甾体类抗炎药、光动力治疗和光凝治疗,但疗效有限且报道有副作用。该研究评估尼达尼布对兔角膜NV的潜在疗效及作用机制。用1mol/L NaOH诱导产生角膜NV21只家兔被随机分为3组,分别用0.9% NaCl5 mg/mL Avastin1 mg/mL尼达尼布处理。结果表明,尼达尼布和Avastin能有效抑制角膜NV,可能与P38 MAPKAKT信号通路有关。尼达尼布似乎比Avastin更有效,有潜力成为一种预防角膜NV的新疗法。

PDF Fulltext

 

CLINICAL RESEARCH

Effects of dietary high dose DHA omega-3 supplement in dry eye with meibomian gland dysfunction

Yeon Ji Jo, Jong Soo Lee

 

The study evaluated the clinical efficacy of dietary supplement of high dose DHA omega-3 in dry eye with meibomian gland dysfunction (MGD). A total of 50 patients were included. Prospective randomized double-masked, placebo-controlled clinical trial was conducted in mild to moderate dry eye patients with MGD. The tear break-up time (TBUT), corneal staining test (NEI), and ocular surface disease index (OSDI) scores significantly improved after 4 and 8wk in both groups. While after 8wk TBUT and MGD score in the omega-3 group was more significantly improved than that of the placebo group. Dry eye with the MGD patient, a high dose of DHA omega-3 dietary supplement can improve TBUT and MGD score after 8wk, effective in stabilizing the tear film.

 

对照译文

高剂量DHA omega-3补充剂对睑板腺功能障碍性干眼症的影响

 

该研究评估了高剂量DHA omega-3补充剂对睑板腺功能障碍性干眼症的临床疗效。在50名患有轻度至中度睑板腺功能障碍性干眼症患者中进行了前瞻性随机双盲、安慰剂对照临床试验。两组的泪膜破裂时间、角膜染色试验和眼表疾病指数评分在4周和8周后均显着改善。而在8周后,omega-3组的泪膜破裂时间和睑板腺功能障碍评分比安慰剂组改善更显著。对于患有睑板腺功能障碍性干眼症患者,高剂量的DHA omega-3膳食补充剂可以在8周后提高泪膜破裂时间和睑板腺功能障碍评分,同时有效稳定泪膜。

PDF Fulltext

 

BRIEF REPORT

A novel temporary keratoprosthesis technique for vitreoretinal surgery

Christos Skevas, Eileen Bigdon, Alexander Steinhorst, Toam Katz, Philipp Schindler, Robert Kromer, Martin Stephan Spitzer

 

A temporary keratoprosthesis (TKP) can be used as an intraoperative bridge between anterior and posterior segment procedures. However, they are only available in certain sizes and may not be immediately at hand when needed. This study aims to investigate the safety of vitreoretinal surgery when using a soft contact lens as a TKP in patients with severe corneal opacifications. The results show that a soft contact lens properly fixated on the globe can successfully replace a TKP. Although using TKP for combined corneal and vitreoretinal surgery is not without complications, it is a valuable tool in the management of complicated ocular cases. The presented novel technique is a safe, easy, and low-cost method to deal with complex corneal and vitreoretinal cases.

 

对照译文

一种用于玻璃体视网膜手术的新型临时人工角膜技术

 

临时人工角膜可作为术中眼前后段之间的桥梁。但是,它们只有特定尺寸且可能无法随时获取。该研究探讨严重角膜混浊患者使用软性接触镜作为临时人工角膜时玻璃体视网膜手术的安全性。研究结果表明将软性接触镜正确地固定在眼球上可以成功地替代临时性人工角膜。虽然使用临时人工角膜进行角膜和玻璃体视网膜联合手术并非没有并发症,但在复杂的眼部病例的治疗中,它是一种有价值的工具。总的来说,这项新技术是一种安全、简便、低成本治疗复杂角膜和玻璃体视网膜病例的方法。

PDF Fulltext

 

To view more excellent articles for free please visit Here.

Published date:2021-10-27Click:

Editors-in-Chief: Yan-Nian Hui and Peter Wiedemann

Established in April, 2008

ISSN 2222-3959 print

ISSN 2227-4898 online

Press search
Search term
From To
  • Most Read
  • Most Cited
  • Article Ranking